Cargando…

RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease

Cardiovascular disease still remains the leading cause of morbidity and mortality worldwide. Current pharmacological or interventional treatments help to tackle symptoms and even reduce mortality, but cardiovascular disease cases continue to rise. The emergence of novel therapeutic strategies that p...

Descripción completa

Detalles Bibliográficos
Autores principales: Birgaoanu, Maria, Sachse, Marco, Gatsiou, Aikaterini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561330/
https://www.ncbi.nlm.nih.gov/pubmed/36239832
http://dx.doi.org/10.1007/s10557-022-07391-3
_version_ 1784807930046971904
author Birgaoanu, Maria
Sachse, Marco
Gatsiou, Aikaterini
author_facet Birgaoanu, Maria
Sachse, Marco
Gatsiou, Aikaterini
author_sort Birgaoanu, Maria
collection PubMed
description Cardiovascular disease still remains the leading cause of morbidity and mortality worldwide. Current pharmacological or interventional treatments help to tackle symptoms and even reduce mortality, but cardiovascular disease cases continue to rise. The emergence of novel therapeutic strategies that precisely and efficiently combat cardiovascular disease is therefore deemed more essential than ever. RNA editing, the cell-intrinsic deamination of adenosine or cytidine RNA residues, changes the molecular identity of edited nucleotides, severely altering the fate of RNA molecules involved in key biological processes. The most common type of RNA editing is the deamination of adenosine residue to inosine (A-to-I), which is catalysed by adenosine deaminases acting on RNA (ADARs). Recent efforts have convincingly liaised RNA editing-based mechanisms to the pathophysiology of the cardiovascular system. In this review, we will briefly introduce the basic concepts of the RNA editing field of research. We will particularly focus our discussion on the therapeutic exploitation of RNA editing as a novel therapeutic tool as well as the future perspectives for its use in cardiovascular disease treatment.
format Online
Article
Text
id pubmed-9561330
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95613302022-10-14 RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease Birgaoanu, Maria Sachse, Marco Gatsiou, Aikaterini Cardiovasc Drugs Ther BSCR Marshall Submissions Cardiovascular disease still remains the leading cause of morbidity and mortality worldwide. Current pharmacological or interventional treatments help to tackle symptoms and even reduce mortality, but cardiovascular disease cases continue to rise. The emergence of novel therapeutic strategies that precisely and efficiently combat cardiovascular disease is therefore deemed more essential than ever. RNA editing, the cell-intrinsic deamination of adenosine or cytidine RNA residues, changes the molecular identity of edited nucleotides, severely altering the fate of RNA molecules involved in key biological processes. The most common type of RNA editing is the deamination of adenosine residue to inosine (A-to-I), which is catalysed by adenosine deaminases acting on RNA (ADARs). Recent efforts have convincingly liaised RNA editing-based mechanisms to the pathophysiology of the cardiovascular system. In this review, we will briefly introduce the basic concepts of the RNA editing field of research. We will particularly focus our discussion on the therapeutic exploitation of RNA editing as a novel therapeutic tool as well as the future perspectives for its use in cardiovascular disease treatment. Springer US 2022-10-14 2023 /pmc/articles/PMC9561330/ /pubmed/36239832 http://dx.doi.org/10.1007/s10557-022-07391-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle BSCR Marshall Submissions
Birgaoanu, Maria
Sachse, Marco
Gatsiou, Aikaterini
RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title_full RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title_fullStr RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title_full_unstemmed RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title_short RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease
title_sort rna editing therapeutics: advances, challenges and perspectives on combating heart disease
topic BSCR Marshall Submissions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561330/
https://www.ncbi.nlm.nih.gov/pubmed/36239832
http://dx.doi.org/10.1007/s10557-022-07391-3
work_keys_str_mv AT birgaoanumaria rnaeditingtherapeuticsadvanceschallengesandperspectivesoncombatingheartdisease
AT sachsemarco rnaeditingtherapeuticsadvanceschallengesandperspectivesoncombatingheartdisease
AT gatsiouaikaterini rnaeditingtherapeuticsadvanceschallengesandperspectivesoncombatingheartdisease